ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: VALUE PROPOSITION-2011

APUA’s Intervention Program/ Objectives:
- Improve institutional and governmental antimicrobial policy
- Strengthen health systems and clinical practice
- Build local microbiology, surveillance and diagnostics capacity
- Increase public awareness and knowledge

ANTIBIOTIC RESISTANCE EXPERTISE AND TOOLS:

RESEARCH
- Multidisciplinary approach/complementary disciplines
- Boston based staff with expertise in medicine, microbiology, public health, health economics, public policy
- Affiliations with Tufts University School of Medicine and esteemed international scientific advisory board
- Engaged APUA chapters/affiliates in 64 countries throughout Africa, Asia, South Pacific and South America.
- Ability to detect and monitor resistance nationally and internationally
- Management of large databases on antimicrobial resistance (AMR)
- Establishment AMR surveillance programs at global and local levels
- Drug quality testing and evaluation
- Microbiology expertise
  - Integration and interpretation of the data to develop treatment guidelines
  - Dr. S. Levy’s laboratories offer the capacity for direct testing and analysis
- Needs assessments and laboratory assessments
- Pharmaceutical supply and distribution research
- Economics of resistance
- Coordinating research consortia and grants in industrial and developing countries
- Researching resistance spread in humans and animals and through soil and water
- Food safety research

Education and advocacy
- Managing antibiotic treatment transitions as resistance emerges
- Policy dissemination and publication
  - Major global disseminator of AMR information via listservs, APUA blog, website and major media outlets
- Education material production for
  - Health Care Providers and Patients
  - Legislators and Ministers of Health
  - Media Communication Specialists
- Stewardship strategies and guidelines development protocols
- Regulatory and policy advocacy and research (national and international)
- Engaging diverse stakeholders from industry, academia and government to forge consensus
- Peer-reviewed research and publications e.g.:  
  - First Global Report on Drug Resistance across major diseases; “The Need to Improve Antimicrobial Use in Agriculture Ecological and Human Health Consequences”, Clinical Infectious Diseases, June 2002
  - Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Stelling, JM, Travers K, Jones RN, Turner PJ, O’Brien TF, Levy SB. Emerging Infectious Diseases 2005
  - First study to document hospital cost of antibiotic resistance in US Hospital and Societal Cost of Antibiotic Resistance, Clinical Infectious Diseases, 2009
- Community organization and advocacy campaigns in developing countries
Full Time Staff at APUA Boston:

Carol Cogliani, Ed.M., M.P.H.; APUA Program Manager
Ms. Cogliani has served as project coordinator for NIH Reservoirs of Antibiotic Resistance (ROAR) project, and a small grants program for developing countries and Pew project analyzing impact of the EU ban on antibiotics for growth promotion in agriculture. Ms. Cogliani previously worked at Harvard Medical School, Harvard School of Public Health.

Susan Foster, Ph.D.; APUA Director of Public Policy and Education
Dr. Foster is a specialist in pharmaceutical policy and economics with extensive experience at the WHO Essential Drugs Programme and at the World Bank’s Population, Health and Nutrition Department. Dr. Foster has extensive field experience in resource-poor countries, utilizing qualitative and quantitative research on cost-effectiveness of health systems. Dr. Foster is a Professor of International Health at Boston University with extensive peer reviewed publications.

Ronald Lanoue, M.B.A.; Operations Manager of APUA
Mr. Lanoue is responsible for financial analysis and program support to ensure the smooth operations of APUA. Mr. Lanoue has extensive experience supporting large USAID and NIH grants and has held senior administrative positions with various medical provider groups and organizations. He received his MBA from Boston University.

Bonnie Marshall, M.T.; APUA’s Research Scientist and Editorial Consultant
Ms. Marshall received her B.A. in Microbiology from the University of New Hampshire and a Medical Technology degree from Framingham State College. Ms. Marshall has over 25 years experience in the management and execution of bench science projects and multiple peer-reviewed journal publications concerning antimicrobial resistance surveillance.

Dorothy Jessica Ochieng, M.Sc.; APUA Project Manager
Ms. Ochieng is a molecular microbiologist with an extensive experience in assessing ABR and AB components in African Countries and in scientific database management. She coordinates projects investigating antibiotic resistance in the environment and in African countries. Ms. Ochieng’s previously led collaborative Biotechnology and genomics projects.

Aníbal Sosa, M.D.; Director of the APUA International Chapter Programs
Dr. Sosa is trained as a microbiologist and infectious disease specialist with considerable experience managing international public health programs in developing countries. He has served as a professor of Medical Microbiology and Tropical Diseases at the University of Zulia School of Medicine and as a clinical instructor at Tufts University School of Medicine. Dr. Sosa provides technical assistance on guidelines development, laboratory strengthening, programs. Dr. Sosa previously served as Director of HIV programs at a Community Health organizations.

Mirella Gonzalez Zulueta, M.D.,Ph.D; Director of Translational Research
Dr. Mirella G. Zulueta is a physician with a Ph.D. in molecular biology and biochemistry and 10+ years experience in the pharmaceutical and health care science fields. Her career has integrated diverse disciplines ranging from genetics, molecular biology, public health advocacy and infectious disease research. She has worked in research and in business development in the field of genomics-based drug discovery and proteomics-based biomarker discovery for several biotech companie and led projects for the Ministry of Research and Innovation of Ontario, Canada. She has a legacy of successful commercialization and development of early-stage discovery projects in therapeutics and diagnostics. Her major interest is research on antibiotic resistance mechanisms to enable the development of interventions. Dr. Zulueta has published over 30 peer reviewed articles and book chapters. Dr. Zulueta’s postdoctoral training was at The Johns Hopkins University School of Medicine.

Kathleen T. Young; Executive Director of APUA
Ms. Young has over 25 years of experience in executive administration of health care payer, provider, consumer, and governmental organizations. Ms. Young is responsible for development of operations, programs and strategic initiatives . Ms. Young is currently serving a four-year term on the U.S. FDA Anti-Infective Drugs Advisory Group, During her 12 year tenure at APUA, Ms. Young has initiated collaborative projects and enjoining diverse stakeholders. Ms. Young was formerly the president of a health advocacy group and Director of Strategic Planning at health provider organizations.

Stuart B. Levy MD; APUA Board Chairman and founder and a past president of the American Society for Microbiology A microbiologist and physician, Dr. Levy discovered the mechanism for tetracycline resistance (efflux) and was among the first to document the transfer of drug resistance among animals and humans. Dr. Levy is the author of The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle and more than 250 scientific and medical papers. He has served as advisor on policy committees including: the NIH Fogarty Cente); the U.S. Office of Technology; the EPA Subcommittees on Health and Antibiotic Resistance; and WHO Scientific Advisory Groups. Dr. Levy has also served as a consultant for the the U.S. FDA, the National Institutes of Health, the U.S. AMRIID national security project. He is currently a Professor of Medicine and Molecular Biology/Microbiology and the Director of the Center for Adaptation Genetics and Drug Resistance at Tufts University School of Medicine, and a Staff Physician at the New England Medical Center.